Klotho

Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc.

Retrieved on: 
Monday, October 2, 2023
Ignition, Bachelor of Science, Boston University Chobanian & Avedisian School of Medicine, Doctor of Philosophy, Harvard University, Pathology, Ageing, Quality of life, Cure, Research, Alzheimer's disease, Multiple sclerosis, Experiment, Advantage, Science, Boston University School of Theology, Biochemistry, Organization, Patient, Immune system, Knowledge, Zenith, DSM-IV codes, Hospital, Pharmacology, Therapy, ALS, NIH, Vienna Biocenter, Caregiver, Disease, Pharmaceutical industry, Vaccine, Tel Aviv University, Neuroscience, Brigham, Klotho, Biology

Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision.

Key Points: 
  • Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision.
  • ADvantage Therapeutics Inc. is currently entering confirmatory Phase 2b clinical trials with its AD04 Alzheimer’s drug candidate, developed at its labs at the Vienna, Austria, BioCenter.
  • Commenting on her new role, Dr. Abraham stated, “Through ADvantage Therapeutics’ pioneering compound AD04, and our exploration of the Klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process.
  • ADvantage Therapeutics, Inc. believes AD04™ stimulates and/or regulates the immune system to reduce Alzheimer’s pathology.

ANEW MEDICAL, INC. To Present at Investor Summit Group's Q4 Conference

Retrieved on: 
Monday, November 7, 2022
Consumer, Sheraton New York Times Square Hotel, LEAS, Founder, Complimentary, OTC Markets Group, Investor, Conference, Real estate, Seventh Avenue, 1X1=1 (To Be One), CEO, Risk, Person, Laboratory, Cancer, Communication services sector reshuffle, Security (finance), Financial services, Technology, Klotho, Health care, Finance

New York, New York--(Newsfile Corp. - November 7, 2022) - ANEW MEDICAL, INC., (OTC Pink: LEAS), today announced that they will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.

Key Points: 
  • New York, New York--(Newsfile Corp. - November 7, 2022) - ANEW MEDICAL, INC., (OTC Pink: LEAS), today announced that they will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.
  • Location: Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York, NY 10019
    1x1s will be available for qualified investors.
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q4 Investor Summit will take place in-person and virtually, featuring 50+ companies and over 300 investors comprised of institutional investors, family offices, and high net worth investors.

U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures

Retrieved on: 
Thursday, October 20, 2022
Sleep apnea, Muscle tissue, Breast augmentation, Depression, Brain, Program, CEO, Patent, Wellness, Personal care, Neurogenic bladder dysfunction, CA, LLC, Invention, Cancer, Mouse, Marketing, Mentorship, United States Patent and Trademark Office, Sleep-related breathing disorder, Skin, GLOBE, Liver failure, FDA, Leonhardt, Time, Amnesia, Stroke, Kidney failure, Cabinet Secretary for Covid Recovery, Research, Regeneration, Procell, Technology, Addiction, Neurology, Body Electric, USPTO, Ageing, Muscle atrophy, Launch pad, Circulatory system, Education, OEM, Lists of diseases, Patient, Biotechnology, Erectile dysfunction, 1836 U.S. Patent Office fire, Partnership, Diabetes, Safety, Heart, Pharmaceutical industry, Dietary supplement, Medical device, Klotho, Longevity

11,471,686 covering bioelectric stimulation control of increasing Klotho, a protein must known for muscle regeneration and other powerful anti-aging properties.

Key Points: 
  • 11,471,686 covering bioelectric stimulation control of increasing Klotho, a protein must known for muscle regeneration and other powerful anti-aging properties.
  • "This Klotho patent adds significant support to our goal mission to help people live longer and healthier lives.
  • In landmark studies, mice deficient in Klotho exhibited accelerated aging and died 30% sooner than mice with normal Klotho levels.
  • The company also intends to launch a chain of Longevity and Wellness MedSpas based on its proprietary core technologies in 2024.

Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market

Retrieved on: 
Friday, April 3, 2020
Branches of biology, Transcription factors, Hepatocellular carcinoma, Hepatology, Brachyury, Klotho, Medical specialties, Medicine

BioArdis will retain all rights to the licensed product in the rest of the world.

Key Points: 
  • BioArdis will retain all rights to the licensed product in the rest of the world.
  • BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC) and other solid tumors positive for FGFR4 and KLB (klotho beta) expression.
  • "We are very excited about the exclusive co-development opportunity for BioArdis' selective FGFR4 inhibitor BIO-1262/SNG-203," commented Dr. Meng Kun, chairman of Beijing Shenogen Pharmaceutical Group.
  • Shenogen aims to develop and commercialize first-in-class therapeutics for cancer and autoimmune diseases.

A Boost of Klotho Protein Level Has Therapeutic Potential in Amyotrophic Lateral Sclerosis (ALS), Also Known as Lou Gehrig's Disease

Retrieved on: 
Thursday, June 27, 2019
Gerontology, Branches of biology, Klotho, Neurodegeneration, Biology, Demography, Ageing

The lead scientists on this study are affiliated with KlogeneTherapeutics, Inc.Klogeneis developing therapies based on increasing the level of Klothoprotein.

Key Points: 
  • The lead scientists on this study are affiliated with KlogeneTherapeutics, Inc.Klogeneis developing therapies based on increasing the level of Klothoprotein.
  • Klotho is a naturally occurring, anti-aging pleiotropic human protein/hormone that has been shown to have potential therapeutic effects in neurodegenerative diseases, kidney disease, certain cancersand more.
  • Preventing Klotho level decline, or increasing it slightly above its level at a young age, is protective, i.e.
  • We suggested back then that a boost in Klotho may have therapeutic potential in neurodegenerative diseases.

NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313

Retrieved on: 
Tuesday, November 6, 2018
Medicine, Clinical medicine, Endocrine system, Peptide hormones, RTT, Eli Lilly and Company, Insulin, Klotho, Biopsy

New data from the 1 mg biopsy cohort will be presented at The Liver Meeting.

Key Points: 
  • New data from the 1 mg biopsy cohort will be presented at The Liver Meeting.
  • In addition to the NGM282 presentations, NGM Bio will present topline data from a Phase 1b study of NGM313, a proprietary, investigational agonistic antibody that selectively activates the -Klotho/FGFR1c receptor complex.
  • NGM313 is being evaluated as a potential once-monthly injectable insulin sensitizer for the treatment of NASH and type 2 diabetes.
  • NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development.